<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307566</url>
  </required_header>
  <id_info>
    <org_study_id>DM2-CPAP</org_study_id>
    <nct_id>NCT01307566</nct_id>
  </id_info>
  <brief_title>Evolution With CPAP Treatment of a Cohort of Type 2 Diabetic Patients With Apnea-hypopnea Syndrome</brief_title>
  <acronym>DM2-CPAP</acronym>
  <official_title>Evolution With CPAP Treatment of a Cohort of Type 2 Diabetic Patients With Moderate to Severe Apnea-hypopnea Syndrome and Poor Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Granollers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EsteveTeijin Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Granollers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to measure the evolution of hemoglobin A1c level after&#xD;
      treatment with CPAP in a cohort of type 2 diabetes mellitus patients with poor glycemic&#xD;
      control and associated moderate or severe obstructive sleep apnea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with poorly controlled type 2 diabetes are a high cardiovascular risk group in which&#xD;
      a high prevalence of moderate to severe sleep apnea is expected. Studies based on&#xD;
      interstitial glycemic measurement demonstrate a reduction in glucose levels when treating&#xD;
      sleep apnea with CPAP. Nevertheless, the effectiveness of CPAP in improving glycemic control&#xD;
      has been questioned as most studies have failed to demonstrate a reduction in hemoglobin A1c&#xD;
      (HbA1C) level over time. Most of these studies have limitations such as a short follow-up or&#xD;
      a suboptimal fulfillment of CPAP treatment. We hypothesize that treating moderate to severe&#xD;
      sleep apnea with CPAP will improve glycemic control (measured by HbA1C) at 14 weeks in good&#xD;
      compliers and that this improvement will be sustained at one year. We aim to test this&#xD;
      hypothesis in consecutive type 2 diabetes patients on stable treatment with HbA1c ≥7% in&#xD;
      routine outpatient visits in our Diabetes, Nutrition and Endocrinology Unit. After providing&#xD;
      informed consent, patients will be screened for sleep apnea by nocturnal oximetry followed by&#xD;
      a diagnostic respiratory polygraphy. Those patients with obstructive sleep apnea with an&#xD;
      apnea-hypopnea index ≥20 will be invited to enter the study. After a 3-month observation&#xD;
      period without any intervention to rule out a potential influence of entering the study on&#xD;
      HbA1C levels, patients will be treated with CPAP. HbA1C levels will be measured at baseline,&#xD;
      after 14 weeks, and thereafter every 14 weeks until completing one year of treatment. Other&#xD;
      endocrine, metabolic and cardiovascular risk variables will be determined at baseline and at&#xD;
      14 weeks of the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobine A1C from baseline</measure>
    <time_frame>14, 28, 42 and 56 weeks after initial intervention.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of fasting glucose from baseline</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self measured capillary glucose profile</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening saliva collection for cortisol assay</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noninvasive 24-hour ambulatory blood pressure monitoring</measure>
    <time_frame>14 weeks after initial intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of urine to assess albumin to creatinine ratio</measure>
    <time_frame>0, 14, 28, and 56 weeks after initial intervention.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of fasting insulin</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of total cholesterol</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of cholesterol HDL</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of tryglicerids</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 v2 Health Survey</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective quantity and quality of sleep reported in a sleep log</measure>
    <time_frame>14 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ratio albumine to creatinine from baseline</measure>
    <time_frame>14, 28, 42 and 56 weeks after initial intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Continuous Positive Airway Pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous Positive Airway Pressure (CPAP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Positive Airway Pressure CPAP</intervention_name>
    <description>CPAP treatment</description>
    <arm_group_label>Continuous Positive Airway Pressure</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Type 2 diabetes on stable treatment for the last three months and HbA1C ≥ 7%&#xD;
&#xD;
          -  Obstructive Sleep Apnea with and apnea-hypopnea index ≥20&#xD;
&#xD;
          -  Acceptance of a therapeutic trial with CPAP&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Race: non caucasic&#xD;
&#xD;
          -  Blood level of hemoglobin &lt;10 in women or &lt;11 in men or iron defitiency or&#xD;
             hemoglobinopathy&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 30&#xD;
&#xD;
          -  Habitual sleeping time &lt;6 hours per night&#xD;
&#xD;
          -  Nocturnal work, shift work or unsual sleeping schedule&#xD;
&#xD;
          -  Primary severe insomnia or secondary to restless legs syndrome&#xD;
&#xD;
          -  Major or non stable psychiatric disorder&#xD;
&#xD;
          -  Treatment with corticosteroids&#xD;
&#xD;
          -  Chronic respiratory disorders that may require corticosteroids or cause respiratory&#xD;
             insufficiency or FEV1/FVC&lt;0.7 with FEV1&lt;50 in spirometry&#xD;
&#xD;
          -  Predominant nocturnal hypoventilation pattern&#xD;
&#xD;
          -  Cardiac failure&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Active CPAP treatment&#xD;
&#xD;
          -  Previous surgery for sleep apnea&#xD;
&#xD;
          -  Severe nasal obstruction&#xD;
&#xD;
          -  Illiteracy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Torrella, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Granollers General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Granollers General Hospital</name>
      <address>
        <city>Granollers</city>
        <state>Barcelnoa</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <last_update_submitted>January 5, 2015</last_update_submitted>
  <last_update_submitted_qc>January 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Granollers</investigator_affiliation>
    <investigator_full_name>marta torrella</investigator_full_name>
    <investigator_title>Chest Physician in Unitat de Pneumologia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

